Drug Profile
ONC 206
Alternative Names: ONC-206Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Oncoceutics
- Developer Chimerix; Oncoceutics
- Class Antineoplastics; Benzyl compounds; Imidazoles; Pyridones; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Endopeptidase Clp stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioma
- Preclinical Liver cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
- No development reported CNS cancer